<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:54:54Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8551925" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8551925</identifier>
        <datestamp>2021-11-04</datestamp>
        <setSpec>nic</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Neuroimage Clin</journal-id>
              <journal-id journal-id-type="iso-abbrev">Neuroimage Clin</journal-id>
              <journal-title-group>
                <journal-title>NeuroImage : Clinical</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2213-1582</issn>
              <publisher>
                <publisher-name>Elsevier</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8551925</article-id>
              <article-id pub-id-type="pmcid">PMC8551925</article-id>
              <article-id pub-id-type="pmc-uid">8551925</article-id>
              <article-id pub-id-type="pmid">34689056</article-id>
              <article-id pub-id-type="pii">S2213-1582(21)00302-8</article-id>
              <article-id pub-id-type="doi">10.1016/j.nicl.2021.102858</article-id>
              <article-id pub-id-type="publisher-id">102858</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Regular Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Measuring brain glucose metabolism in order to predict response to antidepressant or placebo: A randomized clinical trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au005">
                  <name>
                    <surname>Hill</surname>
                    <given-names>Kathryn R.</given-names>
                  </name>
                  <email>kathryn.hill@stonybrookmedicine.edu</email>
                  <xref rid="af005" ref-type="aff">a</xref>
                  <xref rid="cor1" ref-type="corresp">⁎</xref>
                </contrib>
                <contrib contrib-type="author" id="au010">
                  <name>
                    <surname>Gardus</surname>
                    <given-names>John D.</given-names>
                  </name>
                  <email>john.gardus@stonybrookmedicine.edu</email>
                  <xref rid="af005" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au015">
                  <name>
                    <surname>Bartlett</surname>
                    <given-names>Elizabeth A.</given-names>
                  </name>
                  <email>elizabeth.bartlett@nyspi.columbia.edu</email>
                  <xref rid="af010" ref-type="aff">b</xref>
                  <xref rid="af015" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="au020">
                  <name>
                    <surname>Perlman</surname>
                    <given-names>Greg</given-names>
                  </name>
                  <email>greg.perlman@stonybrookmedicine.edu</email>
                  <xref rid="af005" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au025">
                  <name>
                    <surname>Parsey</surname>
                    <given-names>Ramin V.</given-names>
                  </name>
                  <email>ramin.parsey@stonybrookmedicine.edu</email>
                  <xref rid="af005" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au030">
                  <name>
                    <surname>DeLorenzo</surname>
                    <given-names>Christine</given-names>
                  </name>
                  <email>christine.delorenzo@stonybrookmedicine.edu</email>
                  <xref rid="af005" ref-type="aff">a</xref>
                  <xref rid="af015" ref-type="aff">c</xref>
                </contrib>
                <aff id="af005"><label>a</label>Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, 101 Nicolls Rd, Stony Brook, NY, 11794, USA</aff>
                <aff id="af010"><label>b</label>Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA</aff>
                <aff id="af015"><label>c</label>Department of Psychiatry, Columbia University Medical Center, 1051 Riverside Dr, New York, NY 10032, USA</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>⁎</label>Corresponding author at: Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, 101 Nicolls Rd., HSC T-010, Rm. 40D, Stony Brook, NY 11794, USA. <email>kathryn.hill@stonybrookmedicine.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>19</day>
                <month>10</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>19</day>
                <month>10</month>
                <year>2021</year>
              </pub-date>
              <volume>32</volume>
              <elocation-id>102858</elocation-id>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>18</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>12</day>
                  <month>10</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 The Authors</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
                </license>
              </permissions>
              <abstract abstract-type="author-highlights" id="ab005">
                <title>Highlights</title>
                <p>
                  <list list-type="simple" id="l0005">
                    <list-item id="o0005">
                      <label>•</label>
                      <p id="p0005">A clinically relevant method of predicting MDD treatment efficacy is needed.</p>
                    </list-item>
                    <list-item id="o0010">
                      <label>•</label>
                      <p id="p0010">The present investigation applies dynamic FDG-PET using blood as a reference.</p>
                    </list-item>
                    <list-item id="o0015">
                      <label>•</label>
                      <p id="p0015">FDG-PET was assessed in the raphe nuclei, ventral prefrontal cortex and insula.</p>
                    </list-item>
                    <list-item id="o0020">
                      <label>•</label>
                      <p id="p0020">Regional pretreatment metabolism does not relate to symptom severity decrease.</p>
                    </list-item>
                    <list-item id="o0025">
                      <label>•</label>
                      <p id="p0025">Predictive FDG-PET signal may not be generalizable to heterogeneous MDD cohorts.</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <abstract id="ab010">
                <p>There is critical need for a clinically useful tool to predict antidepressant treatment outcome in major depressive disorder (MDD) to reduce suffering and mortality. This analysis sought to build upon previously reported antidepressant treatment efficacy prediction from 2-[<sup>18</sup>F]-fluorodeoxyglucose - Positron Emission Tomography (FDG-PET) using metabolic rate of glucose uptake (MRGlu) from dynamic FDG-PET imaging with the goal of translation to clinical utility. This investigation is a randomized, double-blind placebo-controlled trial. All participants were diagnosed with MDD and received an FDG-PET scan before randomization and after treatment. Hamilton Depression Rating Scale (HDRS-17) was completed in participants diagnosed with MDD before and after 8 weeks of escitalopram, or placebo. MRGlu (mg/(min*100 ml)) was estimated within the raphe nuclei, right insula, and left ventral Prefrontal Cortex in 63 individuals. Linear regression was used to examine the association between pretreatment MRGlu and percent decrease in HDRS-17. Additionally, the association between percent decrease in HDRS-17 and percent change in MRGlu between pretreatment scan and post-treatment scan was examined. Covariates were treatment type (SSRI/placebo), handedness, sex, and age. Depression severity decrease (n = 63) was not significantly associated with pretreatment MRGlu in the raphe nuclei <inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = -2.61e<sup>-03</sup> [-0.26, 0.25], p = 0.98), right insula <inline-formula><mml:math id="M2" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.05 [-0.23, 0.32], p = 0.72), or ventral prefrontal cortex <inline-formula><mml:math id="M3" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.06 [-0.23, 0.34], p = 0.68) where <inline-formula><mml:math id="M4" altimg="si2.svg"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> is the standardized estimated coefficient, with a 95% confidence interval, or in whole brain voxelwise analysis (family-wise error correction, alpha = 0.05). MRGlu percent change was not significantly associated with depression severity decrease (n = 58) before multiple comparison correction in the RN <inline-formula><mml:math id="M5" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.20 [-0.07, 0.47], p = 0.15), right insula <inline-formula><mml:math id="M6" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.24 [-0.03, 0.51], p = 0.08), or vPFC <inline-formula><mml:math id="M7" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.22 [-0.06, 0.50], p = 0.12). We propose that FDG-PET imaging does not indicate a clinically relevant biomarker of escitalopram or placebo treatment response in heterogeneous major depressive disorder cohorts. Future directions include focusing on potential biologically-based subtypes of major depressive disorder by implementing biomarker stratified designs.</p>
              </abstract>
              <kwd-group id="kg005">
                <title>Keywords</title>
                <kwd>Major depressive disorder</kwd>
                <kwd>Treatment response</kwd>
                <kwd>FDG-PET</kwd>
                <kwd>Prediction of response</kwd>
                <kwd>Dynamic imaging</kwd>
              </kwd-group>
              <kwd-group id="kg010">
                <title>Abbreviations</title>
                <kwd>MDD, major depressive disorder</kwd>
                <kwd>SSRIs, selective serotonin reuptake inhibitors</kwd>
                <kwd>PET, Positron Emission Tomography</kwd>
                <kwd>FDG, 2-[<sup>18</sup>F]-fluorodeoxyglucose</kwd>
                <kwd>FDG-PET, 2-[18F]-fluorodeoxyglucose - Positron Emission Tomography</kwd>
                <kwd>MRGlu, metabolic rate of glucose uptake</kwd>
                <kwd>vPFC, ventral prefrontal cortex</kwd>
                <kwd>RN, raphe nuclei</kwd>
                <kwd>SCID-IV, structured clinical interview for diagnosis</kwd>
                <kwd>MADRS, Montgomery–Åsberg Depression Rating Scale</kwd>
                <kwd>HDRS-17, Hamilton Depression Rating Scale</kwd>
                <kwd>5-HT<sub>1A</sub>, serotonin 1A receptor</kwd>
                <kwd>SimE, Simultaneous Estimation</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="s0005">
              <label>1</label>
              <title>Introduction</title>
              <p id="p0030">Over 11 million adults experienced severe impairment due to MDD in 2017 (<xref rid="b0065" ref-type="bibr">Ettman et al., 2020</xref>). Despite this considerable impact on patient wellbeing and productivity, there are currently no objective tools to guide clinicians in choosing antidepressant treatments. To avoid ineffective treatment trials, expedite remission, and thus decrease suffering, there is a need for a clinically useful pretreatment predictive marker of an individual’s course of illness. An objective predictive marker could identify patients’ likelihood to remit following the most commonly used monotherapy for MDD, SSRIs (<xref rid="b0145" ref-type="bibr">Leuchter et al., 2008</xref>). This has been a targeted focus of neuroimaging studies including PET studies.</p>
              <p id="p0035">Among PET investigations, there have been at least seven studies (<xref rid="b0035" ref-type="bibr">Brody et al., 1999</xref>, <xref rid="b0045" ref-type="bibr">Buchsbaum et al., 1997</xref>, <xref rid="b0135" ref-type="bibr">Konarski et al., 2009</xref>, <xref rid="b0150" ref-type="bibr">Little et al., 2005</xref>, <xref rid="b0155" ref-type="bibr">Mayberg et al., 1997</xref>, <xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>, <xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>) targeting a pretreatment marker of antidepressant efficacy through the use of resting state FDG-PET imaging (<xref rid="t0005" ref-type="table">Table 1</xref>). The most notable of the pretreatment prediction studies was conducted by McGrath et al. in 2013, which prompted Dr. Thomas Insel, former National Institute of Mental Health director, to state that FDG-PET was ‘on the cusp’ of clinical utility for treatment guidance (<xref rid="b0005" ref-type="bibr">Asher, 2013</xref>). This study identified higher pretreatment right insula metabolism to be associated with reduction of symptom severity specifically with SSRI treatment. Despite this seminal work and other well-done investigations, FDG-PET has yet to be clinically translated as a technique to predict treatment outcome for MDD patients in the clinic. In the present investigation, we sought to develop this technique as a clinically useful measure.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Prediction study review. Review of studies demonstrating regional predictive signal such that either lower or higher estimates of pretreatment metabolism is associated with decrease in depression severity. This table is divided into ‘Hypothesized regions relevant to present prediction study’, which demonstrates outcomes specific to our regions of interest, the insula and vPFC, and ‘Other regions previously indicated as predictive’, which demonstrates the variability in similar past investigations. Abbreviations: Anterior cingulate cortex (ACC), cognitive behavioral therapy (CBT), dorsolateral prefrontal cortex (DLPFC), electroconvulsive therapy (ECT), Major Depressive Disorder (MDD), prefrontal cortex (PFC), selective serotonin reuptake inhibitor (SSRI), tricyclic antidepressant (TCA), ventral prefrontal cortex (vPFC).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Author</th><th rowspan="2">N, MDD</th><th rowspan="2">Treatment</th><th rowspan="2">FDG Outcome Measure</th><th colspan="2">Hypothesized regions relevant to present prediction study</th><th rowspan="2">Other regions previously indicated as predictive</th></tr><tr><th>Insula</th><th>vPFC</th></tr></thead><tbody><tr><td>(<xref rid="b0155" ref-type="bibr">Mayberg et al., 1997</xref>)</td><td>18</td><td>SSRI (n = 13), TCA or Bupropion (n = 5)</td><td>Relative cerebral metabolic rate for glucose</td><td><bold>Lower</bold></td><td><bold>Lower</bold></td><td><bold>Lower:</bold> DLPFC, premotor cortex <bold>Higher:</bold> rostral ACC</td></tr><tr><td>(<xref rid="b0035" ref-type="bibr">Brody et al., 1999</xref>)</td><td>16</td><td>Paroxetine</td><td>Normalized metabolic values</td><td>–</td><td>–</td><td><bold>Lower:</bold> left ventral ACC</td></tr><tr><td>(<xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>)</td><td>33</td><td>Paroxetine, followed by either another SSRI alone or in combination with non-selective monoamine reuptake inhibitor (n = 20),ECT, or an antidepressant other than paroxetine (n = 13)</td><td>Relative regional cerebral metabolic rate</td><td>–</td><td>–</td><td><bold>Lower:</bold> midbrain including Raphe Nuclei</td></tr><tr><td>(<xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>)</td><td>63</td><td>CBT (n = 33), Escitalopram (n = 30)</td><td>Relative glucose metabolic rates</td><td><bold>Lower:</bold> insula with CBT. <bold>Higher:</bold> insula with SSRI. Right anterior insula most robust.</td><td>–</td><td>–</td></tr><tr><td>(<xref rid="b0045" ref-type="bibr">Buchsbaum et al., 1997</xref>)</td><td>17</td><td>Placebo (n = 10), Sertraline (n = 7)</td><td>Relative metabolic rate</td><td>–</td><td><bold>Higher:</bold> Sertraline</td><td>–</td></tr><tr><td>(<xref rid="b0150" ref-type="bibr">Little et al., 2005</xref>)</td><td>20</td><td>Bupropion or Venlafaxine. Crossed over either treatment (n = 14)</td><td><bold>Dynamic, Quantitative</bold> regional cerebral glucose metabolic rate</td><td><bold>Lower</bold></td><td><bold>Lower</bold></td><td><bold>Lower:</bold> left medial PFC, left amygdala and parahippocampal regions</td></tr><tr><td>(<xref rid="b0135" ref-type="bibr">Konarski et al., 2009</xref>)</td><td>24</td><td>CBT (n = 12), Venlafaxine (n = 12)</td><td>Relative regional glucose metabolism</td><td>–</td><td>–</td><td><bold>Lower:</bold> ventral ACC</td></tr></tbody></table></table-wrap></p>
              <p id="p0040">The most rigorous application (<xref rid="b0030" ref-type="bibr">Boellaard, 2009</xref>) of PET imaging involves a dynamic technique with use of blood as a reference for full quantification of metabolic rate, referred to as metabolic rate of glucose uptake, ‘MRGlu’. The dynamic technique refers to graphical modeling of FDG uptake from regional activity over time for metabolic rate of glucose quantification (<xref rid="b0220" ref-type="bibr">Rahmim et al., 2019</xref>). In the present investigation, we applied this dynamic technique through a randomized, double-blind placebo-controlled trial of the SSRI escitalopram with 63 currently depressed participants. Only one (<xref rid="b0150" ref-type="bibr">Little et al., 2005</xref>) of the seven (<xref rid="b0035" ref-type="bibr">Brody et al., 1999</xref>, <xref rid="b0045" ref-type="bibr">Buchsbaum et al., 1997</xref>, <xref rid="b0135" ref-type="bibr">Konarski et al., 2009</xref>, <xref rid="b0150" ref-type="bibr">Little et al., 2005</xref>, <xref rid="b0155" ref-type="bibr">Mayberg et al., 1997</xref>, <xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>, <xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>) pretreatment studies have applied dynamic technique. In addition, these seven studies have been highly variable in methods, potentially explaining the lack of translation of this technique to clinical utility (<xref rid="b0130" ref-type="bibr">Knudsen et al., 2020</xref>). We hypothesize that the predictive insula metabolism signal in the SSRI group determined in <xref rid="b0160" ref-type="bibr">McGrath et al 2013</xref> will be enhanced through application of dynamic PET imaging technique with blood as a reference. In combination with results from previous FDG-PET investigations, we also hypothesize that pretreatment MRGlu in the left vPFC (<xref rid="b0045" ref-type="bibr">Buchsbaum et al., 1997</xref>, <xref rid="b0150" ref-type="bibr">Little et al., 2005</xref>, <xref rid="b0155" ref-type="bibr">Mayberg et al., 1997</xref>) and the RN (<xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>) will be associated with post-treatment depression severity decrease (referred to as <italic>prediction study</italic>).</p>
              <p id="p0045">While these regions were primarily chosen because of the confluence of data from previous studies indicating their predictive potential, there is also evidence to suggest that these regions are biologically relevant to depression severity decrease. We have shown in previous investigations that high pretreatment raphe nuclei (RN) 5-HT<sub>1A</sub> density is associated with MDD remission (<xref rid="b0185" ref-type="bibr">Miller et al., 2013</xref>). Serotonergic neurons from the RN project throughout the brain. Activation of 5-HT<sub>1A</sub> receptors induces hyperpolarization of these serotonergic neurons, thus inhibiting firing of neuronal action potentials (<xref rid="b0105" ref-type="bibr">Kaufman et al., 2016</xref>), resulting in lower metabolic demand in the RN (<xref rid="b0105" ref-type="bibr">Kaufman et al., 2016</xref>). This finding is therefore consistent with our previous FDG study showing antidepressant remitters have lower pretreatment RN FDG uptake (<xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>). Additionally, insula activity has been associated with interoception, and emotional self-awareness including integration of visceral perception (<xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>) and the vPFC has been implicated in playing a role in regulating negative emotion, specifically through its functional connectivity with the amygdala and anterior cingulate cortex (<xref rid="b0080" ref-type="bibr">Hiser and Koenigs, 2018</xref>).</p>
              <p id="p0050">Additionally, change in glucose metabolism assessed by FDG-PET between pretreatment and post-treatment may be clinically meaningful: it is of interest to determine if potential regional activity change as indicated by FDG-PET is associated with symptom abatement over the course of treatment because this may direct the development of regionally targeted interventions to alleviate symptoms. Specifically, FDG-PET metabolism difference in the insula (<xref rid="b0040" ref-type="bibr">Brody et al., 2001</xref>, <xref rid="b0115" ref-type="bibr">Kennedy et al., 2001</xref>) and left vPFC (<xref rid="b0035" ref-type="bibr">Brody et al., 1999</xref>, <xref rid="b0040" ref-type="bibr">Brody et al., 2001</xref>, <xref rid="b0115" ref-type="bibr">Kennedy et al., 2001</xref>) over the course of treatment has been indicated in previous literature (<xref rid="t0010" ref-type="table">Table 2</xref>). With an additional PET image following treatment, we also analyze the association between MRGlu percent change and depression severity decrease over treatment (referred to as <italic>pre/post study</italic>).<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Pre/post study review. Review of studies demonstrating change in estimates of metabolism between pretreatment scan and post-treatment scan in either all participants, participants with MDD that responded to treatment, or participants given sertraline, but not placebo. This table is divided into ‘Hypothesized regions relevant to present Pre/post study’, which demonstrates outcomes specific to our regions of interest, the insula and vPFC, and ‘Other regions previously indicated as having change in estimates of metabolism in Pre/post study’, which demonstrates the variability in similar past investigations. Abbreviations: Anterior cingulate cortex (ACC), cognitive behavioral therapy (CBT), dorsolateral prefrontal cortex (DLPFC), major depressive disorder (MDD), orbitofrontal cortex (OFC), prefrontal cortex (PFC), ventral prefrontal cortex (vPFC).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Author</th><th rowspan="2">N, MDD Completing the study</th><th rowspan="2">Treatment</th><th rowspan="2">FDG Outcome Measure</th><th rowspan="2">Participant Category</th><th colspan="3">Hypothesized regions relevant to present Pre/post study<hr/></th><th rowspan="2">Other regions previously indicated as having change in estimates of metabolism in Pre/post study</th></tr><tr><th>Insula</th><th colspan="2">vPFC</th></tr></thead><tbody><tr><td>(<xref rid="b0045" ref-type="bibr">Buchsbaum et al., 1997</xref>)</td><td>17</td><td>Placebo (n = 10) Sertraline (n = 7)</td><td>Relative metabolic rate</td><td>MDD treated with sertraline</td><td>–</td><td>–</td><td/><td><bold>Increased</bold>: right parietal lobe and left occipital lobe <bold>Decreased</bold>: right occipital lobe</td></tr><tr><td>(<xref rid="b0035" ref-type="bibr">Brody et al., 1999</xref>)</td><td>16</td><td>Paroxetine</td><td>Normalized metabolic values</td><td>MDD Responders</td><td>–</td><td><bold>Decreased</bold></td><td/><td><bold>Decreased</bold>: OFC</td></tr><tr><td>(<xref rid="b0040" ref-type="bibr">Brody et al., 2001</xref>)</td><td>24</td><td>Paroxetine (n = 10), interpersonal psychotherapy (n = 14)</td><td>Normalized metabolic values</td><td>MDD regardless of outcome</td><td><bold>Increased</bold></td><td><bold>Decreased</bold></td><td/><td><bold>Decreased</bold>: DLPFC and ACC <bold>Increased</bold>: left temporal lobe</td></tr><tr><td>(<xref rid="b0115" ref-type="bibr">Kennedy et al., 2001</xref>)</td><td>13</td><td>Paroxetine</td><td>Relative Regional Brain Glucose Metabolism</td><td>MDD regardless of outcome</td><td><bold>Decreased</bold></td><td><bold>Increased</bold></td><td/><td><bold>Increased</bold>: DLPFC, medial PFC and dorsal ACC <bold>Decreased</bold>: anterior, right hippocampus and parahippocampus</td></tr><tr><td>(<xref rid="b0120" ref-type="bibr">Kennedy et al., 2007</xref>)</td><td>24</td><td>CBT (n = 12), Venlafaxine (n = 12)</td><td>Relative metabolic rate</td><td>MDD Responders</td><td>–</td><td>–</td><td/><td><bold>Decreased</bold>: OFC and right dorsomedial PFC <bold>Increased</bold>: right occipital-temporal cortex</td></tr></tbody></table></table-wrap></p>
              <p id="p0055">Establishing a clinically useful pretreatment predictive marker of an individual’s course of illness is imperative to decrease the disease burden of MDD. Given that FDG is relatively inexpensive and widely used clinically for diagnosis and monitoring conditions such as cancers (<xref rid="b0250" ref-type="bibr">Ziai et al., 2016</xref>), the present investigation brings relevant and impactful information to the field. This study aims to assess clinical translatability of FDG-PET imaging as a means of predicting antidepressant treatment efficacy.</p>
            </sec>
            <sec id="s0010">
              <label>2</label>
              <title>Materials and methods</title>
              <sec id="s0015">
                <label>2.1</label>
                <title>Participant population</title>
                <p id="p0060">The Institutional Review Board of Stony Brook University approved this study. All participants signed informed consent after receiving a complete description of the study, were at least 18 years of age and were recruited as a community sample that responded to an ad in this single center investigation. All participants were diagnosed with current MDD verified by trained rater with the SCID-IV (<xref rid="b0070" ref-type="bibr">First et al., 2002</xref>) and a score of 22 or higher on the MADRS (<xref rid="b0190" ref-type="bibr">Montgomery and Asberg, 1979</xref>). A score of 22 or higher on the MADRS was chosen for inclusion because it has been used in multiple clinical trials to define moderate depression (<xref rid="b0075" ref-type="bibr">Gorwood et al., 2007</xref>, <xref rid="b0095" ref-type="bibr">Iqbal and Mathew, 2020</xref>). Potential participants were excluded under the following conditions: successful current antidepressant treatment, medical contraindications to escitalopram including previous failure of escitalopram therapy, electroconvulsive therapy within 6 months, psychotic disorders (past or current), psychotic symptoms (current), past diagnosis of bipolar disorder, actively suicidal, high potential for excessive substance use during the study period, significant active physical illness, significant neurological deficits, and contraindications to MRI or PET imaging including pregnancy or breast feeding. High potential for excessive substance use was decided by the clinician in conjunction with the study team on an individual basis with reference to the participant’s clinical interview, lifestyle, frequency of current substance use, protective factors and other related information. Handedness was recorded with the Edinburgh Handedness Inventory (<xref rid="b0200" ref-type="bibr">Oldfield, 1971</xref>).</p>
                <p id="p0065">Sample size was determined by power analysis to detect a true correlation as low as 0.39, with 80% power (two-tailed analysis, alpha = 0.05). 613 individuals completed phone screens, 211 signed consent, of whom 125 were eligible and interested (CONSORT diagram, <xref rid="s0155" ref-type="sec">supplemental</xref>). Participants signed full protocol consent before a clinical evaluation was performed to assess exclusion criteria such as presence of bipolar disorder, psychotic symptoms, or indications that the participant was actively suicidal. 85 participants completed pretreatment scan and then were randomized. Seven completed pretreatment scans but did not complete the full course of treatment (lost to follow-up) and were dropped from the study. Three participants were excluded from analysis due to excessive motion or instrument error at pretreatment scan. Additionally, eleven participants with&gt;20% blood glucose change between pre-scan and post-scan sampling were also excluded due to limitations of kinetic FDG uptake modeling, which has decreased accuracy with fluctuating blood glucose over the course of the scan (<xref rid="b0015" ref-type="bibr">Bartlett, 2019</xref>, <xref rid="b0060" ref-type="bibr">Dunn et al., 2009</xref>). Adding in these 11 participants did not alter significance of linear regressions in the <italic>prediction</italic> or <italic>pre/post study</italic>. One participant was dropped due to diabetes, given that abnormalities in insulin response influence blood sugar concentration, which can affect FDG uptake modeling (<xref rid="b0060" ref-type="bibr">Dunn et al., 2009</xref>). 63 participants are included in the <italic>prediction study</italic> but only 58 are included in the <italic>pre/post study</italic> due to failure to complete post-treatment scan (3), uncorrectable image motion in post scan (1), and&gt;20% blood glucose change during the post scan (1). Sample characteristics are described in <xref rid="t0015" ref-type="table">Table 3</xref> and <xref rid="t0020" ref-type="table">Table 4</xref>, as divided by remitters and non-remitters. Remission was defined a priori as post-treatment HDRS-17 less than or equal to 7 (<xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>) and a depression severity decrease of at least 50% (<xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>). Non-remission is defined as not meeting these criteria. HDRS-17 was used in order to maintain consistency with preceding studies of FDG-PET use in remission prediction (<xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>, <xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>) enabling a direct comparison in participant populations.<table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Participant demographics. Non remitters (Non-Rem.) and remitters (Rem.) are compared using a chi-square test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Non-Remitter</th><th colspan="2">Remitter</th><th>p-value for group difference between remitters and non-remitters</th></tr><tr><th/><th>n</th><th>% of Non-Rem.</th><th>n</th><th>% of Rem.</th><th/></tr></thead><tbody><tr><td><bold>Total</bold></td><td>42</td><td>–</td><td>21</td><td>–</td><td rowspan="2">p = 0.10</td></tr><tr><td> Female</td><td>29</td><td>69</td><td>10</td><td>48</td></tr><tr><td>Caucasian</td><td>26</td><td>62</td><td>12</td><td>57</td><td rowspan="2">p = 0.72</td></tr><tr><td>Not Caucasian</td><td>16</td><td>38</td><td>9</td><td>43</td></tr><tr><td>Medication naïve</td><td>20</td><td>50</td><td>6</td><td>30</td><td rowspan="2">p = 0.14</td></tr><tr><td>History of psychotropic medication</td><td>20</td><td>50</td><td>14</td><td>70</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0020"><label>Table 4</label><caption><p>Participant treatment profile. Non-remitters and remitters are compared using independent two-sample <italic>t</italic>-test (<sup>a</sup> significant, p &lt; 0.05). Abbreviations: Major depressive disorder (MDD), Hamilton Depression Rating Scale −17 (HDRS-17).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Non-Remitter</th><th colspan="2">Remitter</th><th rowspan="2">p value for group difference between remitters and non-remitters</th></tr><tr><th>mean</th><th>SD</th><th>mean</th><th>SD</th></tr></thead><tbody><tr><td>Age (years)</td><td align="char">29.92</td><td align="char">13.33</td><td align="char">28.45</td><td align="char">14.93</td><td>p = 0.71</td></tr><tr><td>Age of MDD onset (years)</td><td align="char">23.02</td><td align="char">23.36</td><td align="char">21.81</td><td align="char">20.75</td><td>p = 0.83</td></tr><tr><td>Maximum Treatment Dose given in Study (either escitalopram or placebo, mg)</td><td align="char">29.52</td><td align="char">3.09</td><td align="char">28.10</td><td align="char">6.8</td><td>p = 0.37</td></tr><tr><td>Pretreatment HDRS-17</td><td align="char">18.57</td><td align="char">5.61</td><td align="char">16.00</td><td align="char">3.24</td><td>p = 0.02<sup>a</sup></td></tr><tr><td>Post-treatment HDRS-17</td><td align="char">13.86</td><td align="char">5.22</td><td align="char">4.05</td><td align="char">2.18</td><td>p &lt; 0.01<sup>a</sup></td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="s0020">
                <label>2.2</label>
                <title>Treatment</title>
                <p id="p0070">Participants were either medication naïve or medication free for 3 weeks after completing ineffective psychotropic medication washout before study initiation. Washout was completed over a maximum of 4 weeks before the 3-week psychotropic medication free period. Participants were randomized through a parallel, double-blind design to treatment with either placebo or escitalopram after pretreatment scan. Group allocation for all participants was determined at study initiation by pseudo-random allocation scheme (1:1 ratio) generated by the pharmacist with the software Research Randomizer (<ext-link ext-link-type="uri" xlink:href="http://www.randomizer.org/" id="ir005"><underline>http://www.randomizer.org/</underline></ext-link>). Bottle labelling and medication distribution was completed by the pharmacist, allowing for a double-blind design. Participants met with the study clinician in person each week for the first four weeks, and every other week for the following month. The maximum dosage of medication was 30 mg (3 pills of SSRI or placebo), with a ramp-up period of dosage in intervals of 10 mg (1 pill SSRI or placebo). Specifically, the participants in the treatment arm received 10 mg of escitalopram in week 1, 20 mg in week 2 and 3, and 30 mg in weeks 4–8. This scheduled was altered in the event of treatment intolerance such that titration was increased at a lower rate, maintained, or the dose was decreased. The HDRS-17 was administered prior to pretreatment imaging and after ∼ 8 weeks of treatment, prior to unblinding. The percent decrease between pretreatment and post-treatment HDRS-17 (depression severity decrease) was used as the primary outcome measure. The MADRS (used for inclusion) was not used as an outcome measure in order to maintain independence of symptom rating from inclusion criteria. Through this design, we sought to avoid inflation of symptoms and artificial treatment response. Following unblinding, participants in the placebo group were offered open treatment, and those on escitalopram were offered to continue escitalopram if successful or open treatment if not.</p>
              </sec>
              <sec id="s0025">
                <label>2.3</label>
                <title>Imaging acquisition, reconstruction, and pre-processing</title>
                <sec id="s0030">
                  <label>2.3.1</label>
                  <title>PET processing</title>
                  <p id="p0075">Up to 185 MBq of 2-[18F]-fluorodeoxyglucose (FDG) were injected intravenously and emission data was acquired for 60 min on a Siemens Biograph mMR. Raw listmode PET data were reconstructed offline using Siemens’ e7 Tools software and a CT-like Boston MR-based attenuation map (<xref rid="b0100" ref-type="bibr">Izquierdo-Garcia et al., 2014</xref>, <xref rid="b0140" ref-type="bibr">Ladefoged et al., 2017</xref>). Sinogram files were generated using the following frame definitions: 8x15sec, 6x30sec, 5x60sec, 4x300sec, and 3x600sec. Sinogram data were back-projected with filtering onto a 344x344 matrix with scatter correction and no smoothing. Participant motion was corrected by rigid body registration to a reference frame (<xref rid="b0215" ref-type="bibr">Pillai et al., 2018</xref>) with subsequent coregistration of MRI to the average PET image.</p>
                </sec>
                <sec id="s0035">
                  <label>2.3.2</label>
                  <title>MRI processing</title>
                  <p id="p0080">The insula and vPFC were automatically delineated on the participant’s MRI using atlases as previously described (<xref rid="b0175" ref-type="bibr">Milak et al., 2010</xref>). For voxel analysis and RN delineation (see below, 2.3.3), each participant’s MRI was registered to MNI space using Advanced Normalization Tools (<xref rid="b0010" ref-type="bibr">Avants et al., 2011</xref>). The high resolution MNI template in which the RN was delineated was then registered to subject scan to bring this region into subject space, such that all regions for the region-based analysis were delineated in individual subject space.</p>
                </sec>
                <sec id="s0040">
                  <label>2.3.3</label>
                  <title>RN delineation</title>
                  <p id="p0085">RN delineation was performed using an atlas generated by our group (<ext-link ext-link-type="uri" xlink:href="https://renaissance.stonybrookmedicine.edu/psychiatry/research/cubit/data" id="ir010"><underline>https://renaissance.stonybrookmedicine.edu/psychiatry/research/cubit/data</underline></ext-link>) and is publicly available at this website and upon request. This RN atlas, in MNI space, was created from parametric 5-HT<sub>1A</sub> average binding potential maps generated with the 5-HT<sub>1A</sub> tracer [<sup>11</sup>C]-WAY100635. These maps were then thresholded in the midbrain (<xref rid="b0215" ref-type="bibr">Pillai et al., 2018</xref>).</p>
                </sec>
              </sec>
              <sec id="s0045">
                <label>2.4</label>
                <title>Dynamic analysis</title>
                <p id="p0090">The dynamic technique allows for quantification of MRGlu by modeling FDG uptake and radioactivity in the blood. Average emission activity within each region was calculated per each frame to create the time activity curve. MRGlu was estimated from the time activity curve via the Patlak graphical approach, correcting for blood glucose (blood glucose was averaged from manual blood sampling before and after scanning) and the lumped constant, using an arterial input function recovered via SimE. Traditionally, dynamic and quantitative FDG imaging requires an arterial input function, and thus arterial catheterization, to quantify MRGlu in each brain region. SimE is a mathematical method of calculating the most likely arterial input function by only using one venous blood sample taken after injection of tracer. This technique has been validated and reported on by multiple publications (<xref rid="b0015" ref-type="bibr">Bartlett, 2019</xref>, <xref rid="b0020" ref-type="bibr">Bartlett et al., 2019</xref>, <xref rid="b0195" ref-type="bibr">Ogden et al., 2010</xref>, <xref rid="b0245" ref-type="bibr">Zanderigo et al., 2010</xref>). In brief, SimE fits kinetic models to multiple brain regions of varying kinetics simultaneously and optimizes the estimation of the arterial input function that is common to these regions. The late-scan plasma sample anchors this arterial input function to constrain the range of possible SimE solutions. As previously validated, venous concentrations of FDG are within 5% of arterial concentration after 40 min (<xref rid="b0015" ref-type="bibr">Bartlett, 2019</xref>, <xref rid="b0050" ref-type="bibr">Chen et al., 1998</xref>, <xref rid="b0240" ref-type="bibr">Wakita et al., 2000</xref>) and therefore, can accurately be used as the SimE anchor (<xref rid="b0020" ref-type="bibr">Bartlett et al., 2019</xref>). After the initial run of SimE, the initial imputed plasma and outcome values were used in this work. A single venous plasma sample was acquired at a target time of 40 min (range: 39–43.7 min post injection, 3 participants: 63–75 min, 2 participants: arterial sample at 60 min) and used to anchor the generated arterial input function. Most participants underwent two venous blood draws during the scan (around 40 and 60 min post injection). Reliance on the later venous blood draw for SimE (63–75 min) occurred only when the 40 min sample was not available, for example if there were difficulties in obtaining the blood draw near the 40 min time slot.</p>
              </sec>
              <sec id="s0050">
                <label>2.5</label>
                <title>Statistical Analysis</title>
                <p id="p0095">For all statistical tests, alpha was set at 0.05.</p>
                <sec id="s0055">
                  <label>2.5.1</label>
                  <title>Prediction study</title>
                  <p id="p0100">Linear regression was used to examine the association between pretreatment MRGlu and depression severity decrease ([(pre-treatment HDRS-17 - post-treatment HDRS-17) / pretreatment HDRS-17] * 100). Pretreatment MRGlu was assessed in the 3 regions: RN, right insula, and left vPFC. Treatment type (SSRI or placebo), handedness (continuous variable), sex, and age were covariates.</p>
                </sec>
                <sec id="s0060">
                  <label>2.5.2</label>
                  <title>Pre/post study</title>
                  <p id="p0105">Linear regression was used to examine the association between MRGlu percent change ([(post-treatment MRGlu - pretreatment MRGlu) / pretreatment MRGlu] * 100) and depression severity decrease. MRGlu percent change was assessed in the 3 regions: RN, right insula, and left vPFC. Treatment type (SSRI or placebo), handedness (continuous variable), sex and age were covariates.</p>
                </sec>
              </sec>
              <sec id="s0065">
                <label>2.6</label>
                <title>Image processing for dynamic voxelwise analysis</title>
                <p id="p0110">Voxel maps of MRGlu were generated from the motion corrected co-registered images. MRGlu was calculated by application of the Patlak equation to the time activity curve of each voxel using arterial input function calculated during the regional analysis by SimE. Voxel maps (generated in subject PET space) were warped to MNI standard space using the transformation described above (MRI Processing, 2.3.2) and then smoothed with 8 mm Gaussian kernel. Voxelwise significant cluster analysis was performed using SPM8; Wellcome Trust Centre for Neuroimaging, (<ext-link ext-link-type="uri" xlink:href="http://www.fil.ion.ucl.ac.uk/spm/" id="ir015">http://www.fil.ion.ucl.ac.uk/spm/</ext-link>). A full factorial design with one level was used to assess the relationship between pretreatment MRGlu and depression severity decrease while covarying for age, sex, handedness and treatment type. Family-wise error correction was applied (alpha = 0.05) and extent threshold of 50 voxels.</p>
              </sec>
              <sec id="s0070">
                <label>2.7</label>
                <title>Relative measures comparison</title>
                <p id="p0115">In order to make direct comparison to <xref rid="b0160" ref-type="bibr">McGrath et al’s 2013</xref> study, we replicated their technique as closely as possible (<xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>). The two groups for comparison in that analysis were remitters and non-responders to escitalopram. We followed McGrath’s inclusion criteria to include only participants with a pretreatment HDRS-17 of 15 or higher and defined remitters as attaining a post treatment HDRS-17 less than or equal to 7. Mirroring McGrath, we compared remitters to non-responders, defined as those attaining a decrease in HDRS-17 score of 30% or less. Partial responders were defined by a&gt;30% decrease in HDRS-17 score but this cohort did not meet criteria for remission.</p>
                <p id="p0120">We averaged the last two 10-minute motion corrected co-registered PET frames, divided by injected dose and mean image intensity for generation of static relative glucose metabolic rate emission images. Static voxel images were smoothed with 8 mm Gaussian kernel and then warped to MNI standard space using the transformation described above (MRI Processing). Voxelwise significant cluster analysis was performed using SPM8 with a statistical design of a two-sample <italic>t</italic>-test for group comparison (remitters, non-responders) of pretreatment scan among participants who were randomized to escitalopram. No covariates were used. Family-wise error correction was applied (alpha = 0.05) and extent threshold of 50 voxels.</p>
              </sec>
            </sec>
            <sec id="s0075">
              <label>3</label>
              <title>Results</title>
              <sec id="s0080">
                <label>3.1</label>
                <title>Participants</title>
                <p id="p0125">End of trial enrollment was determined by meeting recruitment goals. See <xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="t0020" ref-type="table">Table 4</xref>. Of the 63 participants included in the <italic>prediction study</italic>, 29 had been prescribed at least one psychotropic medication. Three of the 29 participants did not provide further details of medication history. 22 participants were prescribed at least an SSRI. Of these individuals, six were only prescribed SSRI’s. Ten participants had a medication history of an SSRI and at least another class of antidepressants. Only one individual took a psychotropic medication (stimulant) without a history of antidepressant use. In the 29 participants with history of psychotropic medications, the following medications other than antidepressants were reported: stimulants (n = 5), atypical antipsychotic (n = 3), benzodiazepine (n = 2), buspirone (n = 2), opioids (n = 2), lithium (n = 1) and an anticonvulsant (n = 1). Recruitment began 3/20/2015 and follow-up on the last subject was completed on 3/04/2020.</p>
              </sec>
              <sec id="s0085">
                <label>3.2</label>
                <title>Prediction study</title>
                <p id="p0130">Depression severity decrease was not significantly associated with pretreatment MRGlu (n = 63) before multiple comparison correction in the RN <inline-formula><mml:math id="M8" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = -2.61e<sup>-03</sup> [-0.26, 0.25], p = 0.98), right insula <inline-formula><mml:math id="M9" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.05 [-0.23, 0.32], p = 0.72), or vPFC <inline-formula><mml:math id="M10" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.06 [-0.23, 0.34], p = 0.68) where <inline-formula><mml:math id="M11" altimg="si2.svg"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> is the standardized estimated coefficient, and the 95% confidence interval is reported (<xref rid="f0005" ref-type="fig">Fig. 1</xref>A). Covariates of treatment type, handedness, sex and age were not significantly associated with depression severity decrease after multiple comparisons correction (p &gt; 0.05). <xref rid="f0005" ref-type="fig">Fig. 1</xref> divides remitters from non-remitters along the × axis for visual comparison of outcome measure along the y-axis, although remission was not an aspect of statistical comparison. Of those that received placebo, 13 out of 32 participants achieved remission. Of those that received escitalopram, 8 out of 31 participants achieved remission. As determined with a chi square test, the difference in remission rates was not significant (<inline-formula><mml:math id="M12" altimg="si3.svg"><mml:mrow><mml:mi>χ</mml:mi></mml:mrow></mml:math></inline-formula> = 1.56, p = 0.21).<fig id="f0005"><label>Fig. 1</label><caption><p>Association between Hamilton Depression Rating Scale-17 score percent change between pretreatment and post-treatment and (A.) pretreatment metabolic rate of glucose uptake (MRGlu) (mg/(min*100 ml)) and (B) percent change between pretreatment and post-treatment MRGlu (mg/(min*100 ml)) in the raphe nuclei (RN), left ventral prefrontal cortex (vPFC) and right insula. MRGlu values are derived from regional time activity analysis and not from voxel measures. Positive values on the x-axis indicate depression severity decreased with treatment. Negative values indicate that depression severity increased with treatment. Non-remitters (orange) and remitters (blue) are indicated. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr1"/></fig></p>
              </sec>
              <sec id="s0090">
                <label>3.3</label>
                <title>Pre/post study</title>
                <p id="p0135">MRGlu percent change was not significantly associated with depression severity decrease (n = 58) before multiple comparison correction in the RN <inline-formula><mml:math id="M13" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.20 [-0.07, 0.47], p = 0.15), right insula <inline-formula><mml:math id="M14" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.24 [-0.03, 0.51], p = 0.08), or vPFC <inline-formula><mml:math id="M15" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.22 [-0.06, 0.50], p = 0.12) (<xref rid="f0005" ref-type="fig">Fig. 1</xref>B). Covariates of treatment type, handedness and age were not significantly associated with depression severity decrease (p &gt; 0.05) after multiple comparisons correction. Male sex, relative to female sex, was related to more decrease in depression severity over the course of the study (p &lt; 0.05, after correcting for multiple comparisons).</p>
              </sec>
              <sec id="s0095">
                <label>3.4</label>
                <title>Dynamic voxelwise analysis</title>
                <p id="p0140">There were no significant voxel clusters indicating the association between depression severity decrease and pretreatment MRGlu at an alpha = 0.05 after adjusting for family-wise error while covarying for age, sex, handedness and treatment type.</p>
              </sec>
              <sec id="s0100">
                <label>3.5</label>
                <title>Relative measures comparison</title>
                <p id="p0145">Between remitter (n = 6) and non-responder (n = 11) images of relative glucose metabolic rate acquired pretreatment, there were no significantly different clusters of voxels.</p>
              </sec>
              <sec id="s0105">
                <label>3.6</label>
                <title>Analysis with only medication naïve participants</title>
                <p id="p0150">In a post-hoc analysis, the regional prediction hypotheses were tested with only medication naïve participants (n = 34). The results remained unchanged in that MRGlu percent change was not significantly associated with depression severity decrease in the RN <inline-formula><mml:math id="M16" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = 0.03 [-0.38, 0.43], p = 0.89), right insula <inline-formula><mml:math id="M17" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = -0.03 [-0.48, 0.42], p = 0.90), or vPFC <inline-formula><mml:math id="M18" altimg="si1.svg"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> = -0.03 [-0.46, 0.41], p = 0.90).</p>
              </sec>
            </sec>
            <sec id="s0110">
              <label>4</label>
              <title>Discussion</title>
              <p id="p0155">The present investigation demonstrates that FDG signal alone, analyzed in these ways, is unlikely to be a clinically relevant biomarker of treatment response in MDD that is generalizable to heterogeneous MDD cohorts. This is critical knowledge to allow research time and dollars to be allocated efficiently.</p>
              <p id="p0160">We applied a dynamic technique to calculate MRGlu, in a randomized, double-blind placebo-controlled trial of the SSRI escitalopram. Static imaging techniques generally involve a single PET frame and do not take into account changes in tracer uptake over time. The dynamic technique used in this work differs from a static technique in that it involves modeling of FDG uptake over time and takes into account FDG concentration in plasma and resting plasma blood glucose, allowing absolute quantification of glucose metabolism (<xref rid="b0030" ref-type="bibr">Boellaard, 2009</xref>, <xref rid="b0220" ref-type="bibr">Rahmim et al., 2019</xref>) therefore increasing potential for replicability. Given that glucose and oxygen are the only energy sources for the brain under non-starvation conditions, estimation of glucose metabolism with FDG uptake sensitively measures cerebral functioning based on metabolic demand (<xref rid="b0025" ref-type="bibr">Baxter et al., 1989</xref>). For example, <xref rid="b0160" ref-type="bibr">McGrath et al. 2013</xref> describes the specificity of pretreatment insula metabolism to predict response to the SSRI escitalopram, but not to cognitive behavioral therapy (<xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>). Because previous investigations have demonstrated pretreatment regional glucose metabolism differences associated with likelihood to respond to SSRI’s, we sought to evaluate this association in the present cohort in order to assess replicability and clinical translation of this predictive technique (<xref rid="b0035" ref-type="bibr">Brody et al., 1999</xref>, <xref rid="b0045" ref-type="bibr">Buchsbaum et al., 1997</xref>, <xref rid="b0155" ref-type="bibr">Mayberg et al., 1997</xref>, <xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>, <xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>).</p>
              <p id="p0165">In light of high methodological variability in the literature preceding this study (<xref rid="t0005" ref-type="table">Table 1</xref>), we sought to conduct a rigorous study design. To maintain consistency with preceding studies, HDRS-17 was used (<xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>, <xref rid="b0180" ref-type="bibr">Milak et al., 2009</xref>). Additionally, because two of the three regions of interest were sided (left vPFC, but not right and right insula but not left), handedness was included as a covariate to account for potential effects of differences in hemispheric dominance (<xref rid="b0235" ref-type="bibr">Tandle et al., 2018</xref>). All participants were medication free prior to the pretreatment PET scan for at least three weeks. When analyzing participants who were medication naive independently from those who had a history of psychotropic medication, the primary hypothesis results were unchanged (p-values remained &gt; 0.05) (section 3.6). Post scan data processing underwent rigorous quality control methods. Our investigation determined no association between pretreatment right insula, RN and left vPFC and treatment prediction response.</p>
              <p id="p0170">Absence of a predictive signal, and also the lack of association between MRGlu percent change with depression severity decrease after treatment may be caused by limitations of FDG as a predictive tool for antidepressant efficacy in MDD. This conclusion can be drawn given the lack of replicability in findings in the seven similar studies indicated in <xref rid="t0005" ref-type="table">Table 1</xref>. What may underly this limitation could be the broad heterogeneity of MDD cohorts, reflective of the overall MDD clinical population. In fact, there are 1,497 combinations of eligible diagnostic criteria of DSM-IV that can result in an MDD diagnosis (<xref rid="b0205" ref-type="bibr">Ostergaard et al., 2011</xref>). In addition to heterogeneity of MDD participant characteristics in clinical populations such as symptom combinations, comorbidities and medication history, there is evidence to suggest MDD as a diagnosis is diverse both in presentation characteristics and underlying neurobiology (<xref rid="b0090" ref-type="bibr">Holland et al., 2012</xref>, <xref rid="b0170" ref-type="bibr">Meyer et al., 2020</xref>, <xref rid="b0205" ref-type="bibr">Ostergaard et al., 2011</xref>). <xref rid="b0170" ref-type="bibr">Meyer et al’s 2020</xref> publication in the Lancet Psychiatry notes that in general, biological measurements fail to accurately discern between healthy controls and individuals within diagnosis categories such as MDD. Additionally, there is evidence of large variability in genetic polymorphisms thought to underpin categories of disorders such as MDD (<xref rid="b0170" ref-type="bibr">Meyer et al., 2020</xref>), suggesting MDD itself is not biologically a singular entity. This would further support absence of unified, replicable predictive signal within MDD.</p>
              <p id="p0175">Clinically, the heterogeneity of MDD is well understood including variation in risk factors for MDD development (<xref rid="b0085" ref-type="bibr">Hoare et al., 2020</xref>) and depressive episode relapse (<xref rid="b0125" ref-type="bibr">Kennis et al., 2020</xref>). One way to address this heterogeneity is by implementing a biomarker stratified design (<xref rid="b0090" ref-type="bibr">Holland et al., 2012</xref>). Our group is working towards this in our current project which focuses on identifying MDD patients with neuroinflammation as a potential MDD subtype and treating these patients with anti-inflammatory medication (R01MH123093). This model has potential for expansion to other possible subtypes: neuroimaging investigations are targeting potential biologically based MDD mechanisms including variations in 5-HT<sub>1A</sub> physiology (<xref rid="b0110" ref-type="bibr">Kaufman et al., 2015</xref>) and circadian rhythm disruption (<xref rid="b0165" ref-type="bibr">Mendoza, 2019</xref>).</p>
              <p id="p0180">In a post-hoc analysis (Relative measures comparison, sections 2.7 and 3.5), we employed the same static, relative measures technique of previous investigators (<xref rid="b0160" ref-type="bibr">McGrath et al., 2013</xref>) and could not replicate the findings. Our cohort had similar participant group numbers: remitters (n = 6) and non-responders (n = 11). Comparatively, McGrath had remitters (n = 11) and non-responders (n = 6). Our cohort also had comparable depression severity: the average participant HDRS-17 score for McGrath’s cohort was approximately 19 on average. The average HDRS-17 score in our investigation is 18. However, McGrath’s cohort had a higher average age, in early 40′s, while the average age of this cohort was 29, reflecting the large college population from which many participants were recruited. However, if demographic profile influences study results, the overall applicability of findings to patient populations is limited. Non-replication of significant findings in biomedical research is not rare (<xref rid="b0210" ref-type="bibr">Parsey, 2018</xref>), yet avoidance of research efforts based on non-replicable findings is dependent on publication of negative outcomes (<xref rid="b0055" ref-type="bibr">Collins and Tabak, 2014</xref>). This further emphasizes the need for rigorous validation of techniques aimed at translation to clinical settings.</p>
              <sec id="s0115">
                <label>4.1</label>
                <title>Limitations</title>
                <p id="p0185">Our average age of participants was 29.4 years, reflecting the large college population in our community, which is younger than the average age of previous investigations. However, this age range is reflective of the ideal target population of this study since individuals 18–25 are reported to have the highest prevalence of major depressive episodes (<xref rid="b0225" ref-type="bibr">SAMHSA, 2018</xref>). Ideally, results collected in adults with a similar range of depression severity scores should be replicable to any adult, non-geriatric, general population with similar depression severity. The <italic>pre/post study</italic> demonstrated that the covariate of sex was significantly associated with outcome in all 3 regions after multiple comparisons correction such that male sex was related to decrease in depression severity. This can be seen as a limitation because this is a reversal of what is seen in the literature: males are less likely to respond to treatment than females, with this effect particularly pronounced with SSRI treatment (<xref rid="b0230" ref-type="bibr">Sramek et al., 2016</xref>). This suggests that we may be assessing a cohort which is atypical regarding sex-based MDD characteristics, although this difference is not likely clinically meaningful. Additionally, in 3 out of 121 scans, venous blood samples were collected outside of the 40 min target and instead were collected between 63 and 75 min post injection. This is considered a limitation because these three samples have notable timing variability. However this is unlikely to contribute to outcome measure variability because venous samples taken at both 40 and 60 min post injection have been shown to have FDG activity within 5% of that taken from standard arterial sampling (<xref rid="b0015" ref-type="bibr">Bartlett, 2019</xref>). The analyses were also repeated removing these three participants and the primary hypothesis results were unchanged (p-values remained &gt; 0.05).</p>
              </sec>
            </sec>
            <sec id="s0120">
              <label>5</label>
              <title>Conclusion</title>
              <p id="p0190">We propose that FDG-PET does not indicate a clinically relevant biomarker of treatment response fit for heterogeneous MDD cohorts. Focusing on potential biologically based subtypes of MDD may offer a solution to addressing the important need for treatment outcome prediction for MDD.</p>
            </sec>
            <sec id="s0125">
              <label>6</label>
              <title>Funding and Disclosure</title>
              <sec id="s0130">
                <label>6.1</label>
                <title>Funding</title>
                <p id="p0195">This work was supported by the National Institute of Mental Health [R01MH104512]; the Brain &amp; Behavior Foundation; The Dana Foundation; The New York State Faculty Development Grant; and the National Institute of General Medical Sciences [T32GM008444] which supports Kathryn Hill’s training.</p>
              </sec>
              <sec id="s5555">
                <label>6.2</label>
                <title>Disclosure</title>
                <p id="p0201">Kathryn Hill reports no financial relationships with commercial interests.</p>
                <p id="p202">John Gardus reports no financial relationships with commercial interests.</p>
                <p id="p203">Dr. Bartlett reports no financial relationships with commercial interests.</p>
                <p id="p204">Dr. Perlman reports no financial relationships with commercial interests.</p>
                <p id="p205">Dr. Parsey reports no financial relationships with commercial interests</p>
                <p id="p206">Dr. DeLorenzo reports no financial relationships with commercial interests.</p>
              </sec>
              <sec id="s0135">
                <label>6.3</label>
                <title>Clinical Trials Registration</title>
                <p id="p0200">Advancing Personalized Antidepressant Treatment Using PET/MRI, ClinicalTrials.gov, NCT02623205.</p>
              </sec>
            </sec>
            <sec id="s0140">
              <label>7</label>
              <title>Data and code availability statements</title>
              <p id="p0205">Data is only to be made available via a request to the Authors. The conditions of such a request include:<list list-type="simple" id="l0010"><list-item id="o0030"><label>•</label><p id="p0210">The need for a formal data sharing agreement</p></list-item><list-item id="o0035"><label>•</label><p id="p0215">The need for approval from the requesting researcher's local ethics committee</p></list-item><list-item id="o0040"><label>•</label><p id="p0220">The need to submit a formal project outline</p></list-item><list-item id="o0045"><label>•</label><p id="p0225">Requirements for co-authorship or inclusion in the author byline</p></list-item></list></p>
              <sec id="s0145">
                <title>CRediT authorship contribution statement</title>
                <p id="p0230"><bold>Kathryn R. Hill:</bold> Writing – review &amp; editing, Formal analysis. <bold>John D. Gardus:</bold> Writing – original draft, Formal analysis. <bold>Elizabeth A. Bartlett:</bold> Writing – original draft, Formal analysis. <bold>Greg Perlman:</bold> Writing – original draft, Formal analysis. <bold>Ramin V. Parsey:</bold> Conceptualization, Investigation, Writing – review &amp; editing. <bold>Christine DeLorenzo:</bold> Conceptualization, Investigation, Writing – review &amp; editing, Funding acquisition.</p>
              </sec>
            </sec>
            <sec sec-type="COI-statement">
              <title>Declaration of Competing Interest</title>
              <p id="p0235">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
            </sec>
          </body>
          <back>
            <ref-list id="bi005">
              <title>References</title>
              <ref id="b0005">
                <element-citation publication-type="journal" id="h0005">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Asher</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Scan predicts whether therapy or meds will best lift depression</article-title>
                  <source>NIH News Release.</source>
                  <year>2013</year>
                </element-citation>
              </ref>
              <ref id="b0010">
                <element-citation publication-type="journal" id="h0010">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Avants</surname>
                      <given-names>B.B.</given-names>
                    </name>
                    <name>
                      <surname>Tustison</surname>
                      <given-names>N.J.</given-names>
                    </name>
                    <name>
                      <surname>Song</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>P.A.</given-names>
                    </name>
                    <name>
                      <surname>Klein</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Gee</surname>
                      <given-names>J.C.</given-names>
                    </name>
                  </person-group>
                  <article-title>A reproducible evaluation of ANTs similarity metric performance in brain image registration</article-title>
                  <source>Neuroimage</source>
                  <volume>54</volume>
                  <year>2011</year>
                  <fpage>2033</fpage>
                  <lpage>2044</lpage>
                  <pub-id pub-id-type="pmid">20851191</pub-id>
                </element-citation>
              </ref>
              <ref id="b0015">
                <element-citation publication-type="journal" id="h0015">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bartlett</surname>
                      <given-names>E.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Less-invasive and non-invasive quantification of positron emission tomography data</article-title>
                  <source>ProQuest Dissertations &amp; Theses Global.</source>
                  <year>2019</year>
                  <fpage>48</fpage>
                  <lpage>57</lpage>
                </element-citation>
              </ref>
              <ref id="b0020">
                <element-citation publication-type="journal" id="h0020">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bartlett</surname>
                      <given-names>E.A.</given-names>
                    </name>
                    <name>
                      <surname>Ananth</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Rossano</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>S.F.</given-names>
                    </name>
                    <name>
                      <surname>Nabulsi</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Zanderigo</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.V.</given-names>
                    </name>
                    <name>
                      <surname>DeLorenzo</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantification of Positron Emission Tomography Data Using Simultaneous Estimation of the Input Function: Validation with Venous Blood and Replication of Clinical Studies</article-title>
                  <source>Mol Imaging Biol</source>
                  <volume>21</volume>
                  <year>2019</year>
                  <fpage>926</fpage>
                  <lpage>934</lpage>
                  <pub-id pub-id-type="pmid">30535672</pub-id>
                </element-citation>
              </ref>
              <ref id="b0025">
                <element-citation publication-type="journal" id="h0025">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baxter</surname>
                      <given-names>L.R.</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Phelps</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>Mazziotta</surname>
                      <given-names>J.C.</given-names>
                    </name>
                    <name>
                      <surname>Guze</surname>
                      <given-names>B.H.</given-names>
                    </name>
                    <name>
                      <surname>Selin</surname>
                      <given-names>C.E.</given-names>
                    </name>
                    <name>
                      <surname>Gerner</surname>
                      <given-names>R.H.</given-names>
                    </name>
                    <name>
                      <surname>Sumida</surname>
                      <given-names>R.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Reduction of prefrontal cortex glucose metabolism common to three types of depression</article-title>
                  <source>Arch Gen Psychiatry</source>
                  <volume>46</volume>
                  <year>1989</year>
                  <fpage>243</fpage>
                  <lpage>250</lpage>
                  <pub-id pub-id-type="pmid">2784046</pub-id>
                </element-citation>
              </ref>
              <ref id="b0030">
                <element-citation publication-type="journal" id="h0030">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Boellaard</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Standards for PET image acquisition and quantitative data analysis</article-title>
                  <source>J Nucl Med</source>
                  <volume>50</volume>
                  <issue>Suppl 1</issue>
                  <year>2009</year>
                  <fpage>11s</fpage>
                  <lpage>20s</lpage>
                  <pub-id pub-id-type="pmid">19380405</pub-id>
                </element-citation>
              </ref>
              <ref id="b0035">
                <element-citation publication-type="journal" id="h0035">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brody</surname>
                      <given-names>A.L.</given-names>
                    </name>
                    <name>
                      <surname>Saxena</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Silverman</surname>
                      <given-names>D.H.</given-names>
                    </name>
                    <name>
                      <surname>Alborzian</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Fairbanks</surname>
                      <given-names>L.A.</given-names>
                    </name>
                    <name>
                      <surname>Phelps</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>S.C.</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>H.M.</given-names>
                    </name>
                    <name>
                      <surname>Maidment</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Baxter</surname>
                      <given-names>L.R.</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                  </person-group>
                  <article-title>Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine</article-title>
                  <source>Psychiatry Res</source>
                  <volume>91</volume>
                  <year>1999</year>
                  <fpage>127</fpage>
                  <lpage>139</lpage>
                  <pub-id pub-id-type="pmid">10641577</pub-id>
                </element-citation>
              </ref>
              <ref id="b0040">
                <element-citation publication-type="journal" id="h0040">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brody</surname>
                      <given-names>A.L.</given-names>
                    </name>
                    <name>
                      <surname>Saxena</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Stoessel</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Gillies</surname>
                      <given-names>L.A.</given-names>
                    </name>
                    <name>
                      <surname>Fairbanks</surname>
                      <given-names>L.A.</given-names>
                    </name>
                    <name>
                      <surname>Alborzian</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Phelps</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>S.C.</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>H.M.</given-names>
                    </name>
                    <name>
                      <surname>Ho</surname>
                      <given-names>M.L.</given-names>
                    </name>
                    <name>
                      <surname>Ho</surname>
                      <given-names>M.K.</given-names>
                    </name>
                    <name>
                      <surname>Au</surname>
                      <given-names>S.C.</given-names>
                    </name>
                    <name>
                      <surname>Maidment</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Baxter</surname>
                      <given-names>L.R.</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                  </person-group>
                  <article-title>Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings</article-title>
                  <source>Arch Gen Psychiatry</source>
                  <volume>58</volume>
                  <year>2001</year>
                  <fpage>631</fpage>
                  <lpage>640</lpage>
                  <pub-id pub-id-type="pmid">11448368</pub-id>
                </element-citation>
              </ref>
              <ref id="b0045">
                <element-citation publication-type="journal" id="h0045">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Buchsbaum</surname>
                      <given-names>M.S.</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Siegel</surname>
                      <given-names>B.V.</given-names>
                    </name>
                    <name>
                      <surname>Hackett</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Trenary</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Abel</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Reynolds</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of sertraline on regional metabolic rate in patients with affective disorder</article-title>
                  <source>Biol Psychiatry</source>
                  <volume>41</volume>
                  <year>1997</year>
                  <fpage>15</fpage>
                  <lpage>22</lpage>
                  <pub-id pub-id-type="pmid">8988791</pub-id>
                </element-citation>
              </ref>
              <ref id="b0050">
                <element-citation publication-type="journal" id="h0050">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Bandy</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Reiman</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>S.C.</given-names>
                    </name>
                    <name>
                      <surname>Lawson</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Feng</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Yun</surname>
                      <given-names>L.S.</given-names>
                    </name>
                    <name>
                      <surname>Palant</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Noninvasive quantification of the cerebral metabolic rate for glucose using positron emission tomography, 18F-fluoro-2-deoxyglucose, the Patlak method, and an image-derived input function</article-title>
                  <source>J Cereb Blood Flow Metab</source>
                  <volume>18</volume>
                  <year>1998</year>
                  <fpage>716</fpage>
                  <lpage>723</lpage>
                  <pub-id pub-id-type="pmid">9663501</pub-id>
                </element-citation>
              </ref>
              <ref id="b0055">
                <element-citation publication-type="journal" id="h0055">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Collins</surname>
                      <given-names>F.S.</given-names>
                    </name>
                    <name>
                      <surname>Tabak</surname>
                      <given-names>L.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Policy: NIH plans to enhance reproducibility</article-title>
                  <source>Nature</source>
                  <volume>505</volume>
                  <year>2014</year>
                  <fpage>612</fpage>
                  <lpage>613</lpage>
                  <pub-id pub-id-type="pmid">24482835</pub-id>
                </element-citation>
              </ref>
              <ref id="b0060">
                <element-citation publication-type="journal" id="h0060">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dunn</surname>
                      <given-names>J.T.</given-names>
                    </name>
                    <name>
                      <surname>Anthony</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Amiel</surname>
                      <given-names>S.A.</given-names>
                    </name>
                    <name>
                      <surname>Marsden</surname>
                      <given-names>P.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Correction for the effect of rising plasma glucose levels on quantification of MR(glc) with FDG-PET</article-title>
                  <source>J Cereb Blood Flow Metab</source>
                  <volume>29</volume>
                  <year>2009</year>
                  <fpage>1059</fpage>
                  <lpage>1067</lpage>
                  <pub-id pub-id-type="pmid">19293824</pub-id>
                </element-citation>
              </ref>
              <ref id="b0065">
                <element-citation publication-type="journal" id="h0065">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ettman</surname>
                      <given-names>C.K.</given-names>
                    </name>
                    <name>
                      <surname>Abdalla</surname>
                      <given-names>S.M.</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>G.H.</given-names>
                    </name>
                    <name>
                      <surname>Sampson</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Vivier</surname>
                      <given-names>P.M.</given-names>
                    </name>
                    <name>
                      <surname>Galea</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic</article-title>
                  <source>JAMA Netw Open</source>
                  <volume>3</volume>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e2019686</object-id>
                </element-citation>
              </ref>
              <ref id="b0070">
                <element-citation publication-type="book" id="h0070">
                  <person-group person-group-type="author">
                    <name>
                      <surname>First</surname>
                      <given-names>M.B.</given-names>
                    </name>
                    <name>
                      <surname>Spitzer</surname>
                      <given-names>R.L.</given-names>
                    </name>
                    <name>
                      <surname>Miriam</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>J.B.W.</given-names>
                    </name>
                  </person-group>
                  <part-title>Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition</part-title>
                  <edition>(SCID-I/P).</edition>
                  <year>2002</year>
                  <publisher-name>Biometrics Research, New York State Psychiatric Institute</publisher-name>
                  <publisher-loc>New York</publisher-loc>
                </element-citation>
              </ref>
              <ref id="b0075">
                <element-citation publication-type="journal" id="h0075">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gorwood</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Weiller</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Lemming</surname>
                      <given-names>O.</given-names>
                    </name>
                    <name>
                      <surname>Katona</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Escitalopram prevents relapse in older patients with major depressive disorder</article-title>
                  <source>Am J Geriatr Psychiatry</source>
                  <volume>15</volume>
                  <year>2007</year>
                  <fpage>581</fpage>
                  <lpage>593</lpage>
                  <pub-id pub-id-type="pmid">17586783</pub-id>
                </element-citation>
              </ref>
              <ref id="b0080">
                <element-citation publication-type="journal" id="h0080">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hiser</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Koenigs</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>The Multifaceted Role of the Ventromedial Prefrontal Cortex in Emotion, Decision Making, Social Cognition, and Psychopathology</article-title>
                  <source>Biol Psychiatry</source>
                  <volume>83</volume>
                  <year>2018</year>
                  <fpage>638</fpage>
                  <lpage>647</lpage>
                  <pub-id pub-id-type="pmid">29275839</pub-id>
                </element-citation>
              </ref>
              <ref id="b0085">
                <mixed-citation publication-type="other" id="h0085">Hoare, E., Callaly, E., Berk, M., 2020. Can Depression Be Prevented? If So, How? JAMA Psychiatry.</mixed-citation>
              </ref>
              <ref id="b0090">
                <element-citation publication-type="journal" id="h0090">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Holland</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>McEvoy</surname>
                      <given-names>L.K.</given-names>
                    </name>
                    <name>
                      <surname>Desikan</surname>
                      <given-names>R.S.</given-names>
                    </name>
                    <name>
                      <surname>Dale</surname>
                      <given-names>A.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Enrichment and stratification for predementia Alzheimer disease clinical trials</article-title>
                  <source>PLoS One</source>
                  <volume>7</volume>
                  <year>2012</year>
                  <object-id pub-id-type="publisher-id">e47739</object-id>
                </element-citation>
              </ref>
              <ref id="b0095">
                <element-citation publication-type="journal" id="h0095">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Iqbal</surname>
                      <given-names>S.Z.</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>S.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Ketamine for depression clinical issues</article-title>
                  <source>Adv Pharmacol</source>
                  <volume>89</volume>
                  <year>2020</year>
                  <fpage>131</fpage>
                  <lpage>162</lpage>
                  <pub-id pub-id-type="pmid">32616205</pub-id>
                </element-citation>
              </ref>
              <ref id="b0100">
                <element-citation publication-type="journal" id="h0100">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Izquierdo-Garcia</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Hansen</surname>
                      <given-names>A.E.</given-names>
                    </name>
                    <name>
                      <surname>Forster</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Benoit</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Schachoff</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Furst</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>K.T.</given-names>
                    </name>
                    <name>
                      <surname>Chonde</surname>
                      <given-names>D.B.</given-names>
                    </name>
                    <name>
                      <surname>Catana</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>An SPM8-based approach for attenuation correction combining segmentation and nonrigid template formation: application to simultaneous PET/MR brain imaging</article-title>
                  <source>J Nucl Med</source>
                  <volume>55</volume>
                  <year>2014</year>
                  <fpage>1825</fpage>
                  <lpage>1830</lpage>
                  <pub-id pub-id-type="pmid">25278515</pub-id>
                </element-citation>
              </ref>
              <ref id="b0105">
                <element-citation publication-type="journal" id="h0105">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kaufman</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>DeLorenzo</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Choudhury</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.V.</given-names>
                    </name>
                  </person-group>
                  <article-title>The 5-HT1A receptor in Major Depressive Disorder</article-title>
                  <source>Eur Neuropsychopharmacol</source>
                  <volume>26</volume>
                  <year>2016</year>
                  <fpage>397</fpage>
                  <lpage>410</lpage>
                  <pub-id pub-id-type="pmid">26851834</pub-id>
                </element-citation>
              </ref>
              <ref id="b0110">
                <element-citation publication-type="journal" id="h0110">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kaufman</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>G.M.</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Ogden</surname>
                      <given-names>R.T.</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Oquendo</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.V.</given-names>
                    </name>
                    <name>
                      <surname>DeLorenzo</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantification of the Serotonin 1A Receptor Using PET: Identification of a Potential Biomarker of Major Depression in Males</article-title>
                  <source>Neuropsychopharmacology</source>
                  <volume>40</volume>
                  <year>2015</year>
                  <fpage>1692</fpage>
                  <lpage>1699</lpage>
                  <pub-id pub-id-type="pmid">25578798</pub-id>
                </element-citation>
              </ref>
              <ref id="b0115">
                <element-citation publication-type="journal" id="h0115">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kennedy</surname>
                      <given-names>S.H.</given-names>
                    </name>
                    <name>
                      <surname>Evans</surname>
                      <given-names>K.R.</given-names>
                    </name>
                    <name>
                      <surname>Kruger</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Mayberg</surname>
                      <given-names>H.S.</given-names>
                    </name>
                    <name>
                      <surname>Meyer</surname>
                      <given-names>J.H.</given-names>
                    </name>
                    <name>
                      <surname>McCann</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Arifuzzman</surname>
                      <given-names>A.I.</given-names>
                    </name>
                    <name>
                      <surname>Houle</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Vaccarino</surname>
                      <given-names>F.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression</article-title>
                  <source>Am J Psychiatry</source>
                  <volume>158</volume>
                  <year>2001</year>
                  <fpage>899</fpage>
                  <lpage>905</lpage>
                  <pub-id pub-id-type="pmid">11384897</pub-id>
                </element-citation>
              </ref>
              <ref id="b0120">
                <element-citation publication-type="journal" id="h0120">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kennedy</surname>
                      <given-names>S.H.</given-names>
                    </name>
                    <name>
                      <surname>Konarski</surname>
                      <given-names>J.Z.</given-names>
                    </name>
                    <name>
                      <surname>Segal</surname>
                      <given-names>Z.V.</given-names>
                    </name>
                    <name>
                      <surname>Lau</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Bieling</surname>
                      <given-names>P.J.</given-names>
                    </name>
                    <name>
                      <surname>McIntyre</surname>
                      <given-names>R.S.</given-names>
                    </name>
                    <name>
                      <surname>Mayberg</surname>
                      <given-names>H.S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial</article-title>
                  <source>Am J Psychiatry</source>
                  <volume>164</volume>
                  <year>2007</year>
                  <fpage>778</fpage>
                  <lpage>788</lpage>
                  <pub-id pub-id-type="pmid">17475737</pub-id>
                </element-citation>
              </ref>
              <ref id="b0125">
                <element-citation publication-type="journal" id="h0125">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kennis</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Gerritsen</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>van Dalen</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Cuijpers</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Bockting</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis</article-title>
                  <source>Mol Psychiatry</source>
                  <volume>25</volume>
                  <year>2020</year>
                  <fpage>321</fpage>
                  <lpage>338</lpage>
                  <pub-id pub-id-type="pmid">31745238</pub-id>
                </element-citation>
              </ref>
              <ref id="b0130">
                <element-citation publication-type="journal" id="h0130">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Knudsen</surname>
                      <given-names>G.M.</given-names>
                    </name>
                    <name>
                      <surname>Ganz</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Appelhoff</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Boellaard</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Bormans</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Carson</surname>
                      <given-names>R.E.</given-names>
                    </name>
                    <name>
                      <surname>Catana</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Doudet</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Gee</surname>
                      <given-names>A.D.</given-names>
                    </name>
                    <name>
                      <surname>Greve</surname>
                      <given-names>D.N.</given-names>
                    </name>
                    <name>
                      <surname>Gunn</surname>
                      <given-names>R.N.</given-names>
                    </name>
                    <name>
                      <surname>Halldin</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Herscovitch</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Keller</surname>
                      <given-names>S.H.</given-names>
                    </name>
                    <name>
                      <surname>Lammertsma</surname>
                      <given-names>A.A.</given-names>
                    </name>
                    <name>
                      <surname>Lanzenberger</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Liow</surname>
                      <given-names>J.S.</given-names>
                    </name>
                    <name>
                      <surname>Lohith</surname>
                      <given-names>T.G.</given-names>
                    </name>
                    <name>
                      <surname>Lubberink</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Lyoo</surname>
                      <given-names>C.H.</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Matheson</surname>
                      <given-names>G.J.</given-names>
                    </name>
                    <name>
                      <surname>Nichols</surname>
                      <given-names>T.E.</given-names>
                    </name>
                    <name>
                      <surname>Nørgaard</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Ogden</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Pike</surname>
                      <given-names>V.W.</given-names>
                    </name>
                    <name>
                      <surname>Price</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Rizzo</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Rosa-Neto</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Schain</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>P.J.</given-names>
                    </name>
                    <name>
                      <surname>Searle</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Slifstein</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Suhara</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Talbot</surname>
                      <given-names>P.S.</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Veronese</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Wong</surname>
                      <given-names>D.F.</given-names>
                    </name>
                    <name>
                      <surname>Yaqub</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Zanderigo</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Zoghbi</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Innis</surname>
                      <given-names>R.B.</given-names>
                    </name>
                  </person-group>
                  <article-title>Guidelines for the content and format of PET brain data in publications and archives: A consensus paper</article-title>
                  <source>J Cereb Blood Flow Metab</source>
                  <volume>40</volume>
                  <year>2020</year>
                  <fpage>1576</fpage>
                  <lpage>1585</lpage>
                  <pub-id pub-id-type="pmid">32065076</pub-id>
                </element-citation>
              </ref>
              <ref id="b0135">
                <element-citation publication-type="journal" id="h0135">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Konarski</surname>
                      <given-names>J.Z.</given-names>
                    </name>
                    <name>
                      <surname>Kennedy</surname>
                      <given-names>S.H.</given-names>
                    </name>
                    <name>
                      <surname>Segal</surname>
                      <given-names>Z.V.</given-names>
                    </name>
                    <name>
                      <surname>Lau</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Bieling</surname>
                      <given-names>P.J.</given-names>
                    </name>
                    <name>
                      <surname>McIntyre</surname>
                      <given-names>R.S.</given-names>
                    </name>
                    <name>
                      <surname>Mayberg</surname>
                      <given-names>H.S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder</article-title>
                  <source>J Psychiatry Neurosci</source>
                  <volume>34</volume>
                  <year>2009</year>
                  <fpage>175</fpage>
                  <lpage>180</lpage>
                  <pub-id pub-id-type="pmid">19448846</pub-id>
                </element-citation>
              </ref>
              <ref id="b0140">
                <element-citation publication-type="journal" id="h0140">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ladefoged</surname>
                      <given-names>C.N.</given-names>
                    </name>
                    <name>
                      <surname>Law</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Anazodo</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>St Lawrence</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Izquierdo-Garcia</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Catana</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Burgos</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Cardoso</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Ourselin</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hutton</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Merida</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Costes</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Hammers</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Benoit</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Holm</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Juttukonda</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>An</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Cabello</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Lukas</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Nekolla</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Ziegler</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Fenchel</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Jakoby</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Casey</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>Benzinger</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Hojgaard</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Hansen</surname>
                      <given-names>A.E.</given-names>
                    </name>
                    <name>
                      <surname>Andersen</surname>
                      <given-names>F.L.</given-names>
                    </name>
                  </person-group>
                  <article-title>A multi-centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients</article-title>
                  <source>Neuroimage</source>
                  <volume>147</volume>
                  <year>2017</year>
                  <fpage>346</fpage>
                  <lpage>359</lpage>
                  <pub-id pub-id-type="pmid">27988322</pub-id>
                </element-citation>
              </ref>
              <ref id="b0145">
                <element-citation publication-type="journal" id="h0145">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leuchter</surname>
                      <given-names>A.F.</given-names>
                    </name>
                    <name>
                      <surname>Lesser</surname>
                      <given-names>I.M.</given-names>
                    </name>
                    <name>
                      <surname>Trivedi</surname>
                      <given-names>M.H.</given-names>
                    </name>
                    <name>
                      <surname>Rush</surname>
                      <given-names>A.J.</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>D.W.</given-names>
                    </name>
                    <name>
                      <surname>Warden</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Fava</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Wisniewski</surname>
                      <given-names>S.R.</given-names>
                    </name>
                    <name>
                      <surname>Luther</surname>
                      <given-names>J.F.</given-names>
                    </name>
                    <name>
                      <surname>Perales</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Gaynes</surname>
                      <given-names>B.N.</given-names>
                    </name>
                    <name>
                      <surname>Stewart</surname>
                      <given-names>J.W.</given-names>
                    </name>
                  </person-group>
                  <article-title>An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder</article-title>
                  <source>J Psychiatr Pract</source>
                  <volume>14</volume>
                  <year>2008</year>
                  <fpage>271</fpage>
                  <lpage>280</lpage>
                  <pub-id pub-id-type="pmid">18832958</pub-id>
                </element-citation>
              </ref>
              <ref id="b0150">
                <element-citation publication-type="journal" id="h0150">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Little</surname>
                      <given-names>J.T.</given-names>
                    </name>
                    <name>
                      <surname>Ketter</surname>
                      <given-names>T.A.</given-names>
                    </name>
                    <name>
                      <surname>Kimbrell</surname>
                      <given-names>T.A.</given-names>
                    </name>
                    <name>
                      <surname>Dunn</surname>
                      <given-names>R.T.</given-names>
                    </name>
                    <name>
                      <surname>Benson</surname>
                      <given-names>B.E.</given-names>
                    </name>
                    <name>
                      <surname>Willis</surname>
                      <given-names>M.W.</given-names>
                    </name>
                    <name>
                      <surname>Luckenbaugh</surname>
                      <given-names>D.A.</given-names>
                    </name>
                    <name>
                      <surname>Post</surname>
                      <given-names>R.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression</article-title>
                  <source>Biol Psychiatry</source>
                  <volume>57</volume>
                  <year>2005</year>
                  <fpage>220</fpage>
                  <lpage>228</lpage>
                  <pub-id pub-id-type="pmid">15691522</pub-id>
                </element-citation>
              </ref>
              <ref id="b0155">
                <element-citation publication-type="journal" id="h0155">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mayberg</surname>
                      <given-names>H.S.</given-names>
                    </name>
                    <name>
                      <surname>Brannan</surname>
                      <given-names>S.K.</given-names>
                    </name>
                    <name>
                      <surname>Mahurin</surname>
                      <given-names>R.K.</given-names>
                    </name>
                    <name>
                      <surname>Jerabek</surname>
                      <given-names>P.A.</given-names>
                    </name>
                    <name>
                      <surname>Brickman</surname>
                      <given-names>J.S.</given-names>
                    </name>
                    <name>
                      <surname>Tekell</surname>
                      <given-names>J.L.</given-names>
                    </name>
                    <name>
                      <surname>Silva</surname>
                      <given-names>J.A.</given-names>
                    </name>
                    <name>
                      <surname>McGinnis</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Glass</surname>
                      <given-names>T.G.</given-names>
                    </name>
                    <name>
                      <surname>Martin</surname>
                      <given-names>C.C.</given-names>
                    </name>
                    <name>
                      <surname>Fox</surname>
                      <given-names>P.T.</given-names>
                    </name>
                  </person-group>
                  <article-title>Cingulate function in depression: a potential predictor of treatment response</article-title>
                  <source>Neuroreport</source>
                  <volume>8</volume>
                  <year>1997</year>
                  <fpage>1057</fpage>
                  <lpage>1061</lpage>
                  <pub-id pub-id-type="pmid">9141092</pub-id>
                </element-citation>
              </ref>
              <ref id="b0160">
                <element-citation publication-type="journal" id="h0160">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McGrath</surname>
                      <given-names>C.L.</given-names>
                    </name>
                    <name>
                      <surname>Kelley</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>Holtzheimer</surname>
                      <given-names>P.E.</given-names>
                    </name>
                    <name>
                      <surname>Dunlop</surname>
                      <given-names>B.W.</given-names>
                    </name>
                    <name>
                      <surname>Craighead</surname>
                      <given-names>W.E.</given-names>
                    </name>
                    <name>
                      <surname>Franco</surname>
                      <given-names>A.R.</given-names>
                    </name>
                    <name>
                      <surname>Craddock</surname>
                      <given-names>R.C.</given-names>
                    </name>
                    <name>
                      <surname>Mayberg</surname>
                      <given-names>H.S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Toward a neuroimaging treatment selection biomarker for major depressive disorder</article-title>
                  <source>JAMA Psychiatry</source>
                  <volume>70</volume>
                  <year>2013</year>
                  <fpage>821</fpage>
                  <lpage>829</lpage>
                  <pub-id pub-id-type="pmid">23760393</pub-id>
                </element-citation>
              </ref>
              <ref id="b0165">
                <element-citation publication-type="journal" id="h0165">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mendoza</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Circadian insights into the biology of depression: Symptoms, treatments and animal models</article-title>
                  <source>Behav Brain Res</source>
                  <volume>376</volume>
                  <year>2019</year>
                  <object-id pub-id-type="publisher-id">112186</object-id>
                </element-citation>
              </ref>
              <ref id="b0170">
                <element-citation publication-type="journal" id="h0170">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meyer</surname>
                      <given-names>J.H.</given-names>
                    </name>
                    <name>
                      <surname>Cervenka</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Kreisl</surname>
                      <given-names>W.C.</given-names>
                    </name>
                    <name>
                      <surname>Henter</surname>
                      <given-names>I.D.</given-names>
                    </name>
                    <name>
                      <surname>Innis</surname>
                      <given-names>R.B.</given-names>
                    </name>
                  </person-group>
                  <article-title>Neuroinflammation in psychiatric disorders: PET imaging and promising new targets</article-title>
                  <source>Lancet Psychiatry</source>
                  <volume>7</volume>
                  <year>2020</year>
                  <fpage>1064</fpage>
                  <lpage>1074</lpage>
                  <pub-id pub-id-type="pmid">33098761</pub-id>
                </element-citation>
              </ref>
              <ref id="b0175">
                <element-citation publication-type="journal" id="h0175">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Milak</surname>
                      <given-names>M.S.</given-names>
                    </name>
                    <name>
                      <surname>DeLorenzo</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Zanderigo</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Prabhakaran</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Kumar</surname>
                      <given-names>J.S.</given-names>
                    </name>
                    <name>
                      <surname>Majo</surname>
                      <given-names>V.J.</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.V.</given-names>
                    </name>
                  </person-group>
                  <article-title>In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer</article-title>
                  <source>J Nucl Med</source>
                  <volume>51</volume>
                  <year>2010</year>
                  <fpage>1892</fpage>
                  <lpage>1900</lpage>
                  <pub-id pub-id-type="pmid">21098796</pub-id>
                </element-citation>
              </ref>
              <ref id="b0180">
                <element-citation publication-type="journal" id="h0180">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Milak</surname>
                      <given-names>M.S.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.V.</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Oquendo</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Olvet</surname>
                      <given-names>D.M.</given-names>
                    </name>
                    <name>
                      <surname>Eipper</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Malone</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>J.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment</article-title>
                  <source>Psychiatry Res</source>
                  <volume>173</volume>
                  <year>2009</year>
                  <fpage>63</fpage>
                  <lpage>70</lpage>
                  <pub-id pub-id-type="pmid">19446443</pub-id>
                </element-citation>
              </ref>
              <ref id="b0185">
                <element-citation publication-type="journal" id="h0185">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Hesselgrave</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Ogden</surname>
                      <given-names>R.T.</given-names>
                    </name>
                    <name>
                      <surname>Zanderigo</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Oquendo</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.V.</given-names>
                    </name>
                  </person-group>
                  <article-title>Brain serotonin 1A receptor binding as a predictor of treatment outcome in major depressive disorder</article-title>
                  <source>Biol Psychiatry</source>
                  <volume>74</volume>
                  <year>2013</year>
                  <fpage>760</fpage>
                  <lpage>767</lpage>
                  <pub-id pub-id-type="pmid">23664414</pub-id>
                </element-citation>
              </ref>
              <ref id="b0190">
                <element-citation publication-type="journal" id="h0190">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Montgomery</surname>
                      <given-names>S.A.</given-names>
                    </name>
                    <name>
                      <surname>Asberg</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>A new depression scale designed to be sensitive to change</article-title>
                  <source>Br J Psychiatry</source>
                  <volume>134</volume>
                  <year>1979</year>
                  <fpage>382</fpage>
                  <lpage>389</lpage>
                  <pub-id pub-id-type="pmid">444788</pub-id>
                </element-citation>
              </ref>
              <ref id="b0195">
                <element-citation publication-type="journal" id="h0195">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ogden</surname>
                      <given-names>R.T.</given-names>
                    </name>
                    <name>
                      <surname>Zanderigo</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Choy</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.V.</given-names>
                    </name>
                  </person-group>
                  <article-title>Simultaneous estimation of input functions: an empirical study</article-title>
                  <source>J Cereb Blood Flow Metab</source>
                  <volume>30</volume>
                  <year>2010</year>
                  <fpage>816</fpage>
                  <lpage>826</lpage>
                  <pub-id pub-id-type="pmid">19997119</pub-id>
                </element-citation>
              </ref>
              <ref id="b0200">
                <element-citation publication-type="journal" id="h0200">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Oldfield</surname>
                      <given-names>R.C.</given-names>
                    </name>
                  </person-group>
                  <article-title>The assessment and analysis of handedness: the Edinburgh inventory</article-title>
                  <source>Neuropsychologia</source>
                  <volume>9</volume>
                  <year>1971</year>
                  <fpage>97</fpage>
                  <lpage>113</lpage>
                  <pub-id pub-id-type="pmid">5146491</pub-id>
                </element-citation>
              </ref>
              <ref id="b0205">
                <element-citation publication-type="journal" id="h0205">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ostergaard</surname>
                      <given-names>S.D.</given-names>
                    </name>
                    <name>
                      <surname>Jensen</surname>
                      <given-names>S.O.</given-names>
                    </name>
                    <name>
                      <surname>Bech</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>The heterogeneity of the depressive syndrome: when numbers get serious</article-title>
                  <source>Acta Psychiatr Scand</source>
                  <volume>124</volume>
                  <year>2011</year>
                  <fpage>495</fpage>
                  <lpage>496</lpage>
                  <pub-id pub-id-type="pmid">21838736</pub-id>
                </element-citation>
              </ref>
              <ref id="b0210">
                <element-citation publication-type="journal" id="h0210">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>The Importance of Publishing Negative Findings in Science</article-title>
                  <source>Biol Psychiatry</source>
                  <volume>84</volume>
                  <year>2018</year>
                  <fpage>550</fpage>
                  <pub-id pub-id-type="pmid">30261974</pub-id>
                </element-citation>
              </ref>
              <ref id="b0215">
                <element-citation publication-type="journal" id="h0215">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pillai</surname>
                      <given-names>R.L.I.</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Boldrini</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Oquendo</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Parsey</surname>
                      <given-names>R.V.</given-names>
                    </name>
                    <name>
                      <surname>DeLorenzo</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Will imaging individual raphe nuclei in males with major depressive disorder enhance diagnostic sensitivity and specificity?</article-title>
                  <source>Depress Anxiety</source>
                  <volume>35</volume>
                  <year>2018</year>
                  <fpage>411</fpage>
                  <lpage>420</lpage>
                  <pub-id pub-id-type="pmid">29365217</pub-id>
                </element-citation>
              </ref>
              <ref id="b0220">
                <element-citation publication-type="journal" id="h0220">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rahmim</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Lodge</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Karakatsanis</surname>
                      <given-names>N.A.</given-names>
                    </name>
                    <name>
                      <surname>Panin</surname>
                      <given-names>V.Y.</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>McMillan</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Cho</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Zaidi</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Casey</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>Wahl</surname>
                      <given-names>R.L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Dynamic whole-body PET imaging: principles, potentials and applications</article-title>
                  <source>Eur J Nucl Med Mol Imaging</source>
                  <volume>46</volume>
                  <year>2019</year>
                  <fpage>501</fpage>
                  <lpage>518</lpage>
                  <pub-id pub-id-type="pmid">30269154</pub-id>
                </element-citation>
              </ref>
              <ref id="b0225">
                <mixed-citation publication-type="other" id="h0225">SAMHSA, 2018. 2017 National Survey on Drug Use and Health: Methodological summary and definitions., Center for Behavioral Health Statistics and Quality. Substance Abuse And Mental Health Services Administration, Rockville, MD.</mixed-citation>
              </ref>
              <ref id="b0230">
                <element-citation publication-type="journal" id="h0230">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sramek</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>M.F.</given-names>
                    </name>
                    <name>
                      <surname>Cutler</surname>
                      <given-names>N.R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Sex differences in the psychopharmacological treatment of depression</article-title>
                  <source>Dialogues Clin Neurosci</source>
                  <volume>18</volume>
                  <year>2016</year>
                  <fpage>447</fpage>
                  <lpage>457</lpage>
                  <pub-id pub-id-type="pmid">28179816</pub-id>
                </element-citation>
              </ref>
              <ref id="b0235">
                <element-citation publication-type="journal" id="h0235">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tandle</surname>
                      <given-names>A.L.</given-names>
                    </name>
                    <name>
                      <surname>Joshi</surname>
                      <given-names>M.S.</given-names>
                    </name>
                    <name>
                      <surname>Dharmadhikari</surname>
                      <given-names>A.S.</given-names>
                    </name>
                    <name>
                      <surname>Jaiswal</surname>
                      <given-names>S.V.</given-names>
                    </name>
                  </person-group>
                  <article-title>Mental state and emotion detection from musically stimulated EEG</article-title>
                  <source>Brain Inform</source>
                  <volume>5</volume>
                  <year>2018</year>
                  <fpage>14</fpage>
                  <pub-id pub-id-type="pmid">30499008</pub-id>
                </element-citation>
              </ref>
              <ref id="b0240">
                <element-citation publication-type="journal" id="h0240">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wakita</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Imahori</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Ido</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Fujii</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Horii</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Shimizu</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Nakajima</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Mineura</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Nakamura</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Kanatsuna</surname>
                      <given-names>T.</given-names>
                    </name>
                  </person-group>
                  <article-title>Simplification for measuring input function of FDG PET: investigation of 1-point blood sampling method</article-title>
                  <source>J Nucl Med</source>
                  <volume>41</volume>
                  <year>2000</year>
                  <fpage>1484</fpage>
                  <lpage>1490</lpage>
                  <pub-id pub-id-type="pmid">10994726</pub-id>
                </element-citation>
              </ref>
              <ref id="b0245">
                <mixed-citation publication-type="other" id="h0245">Zanderigo, F., Ogden, R. T., Mann, J. J. Parsey, R. V.,, 2010. A voxel-based clustering approach for the automatic selection of testing regions in the simultaneous estimation of input functions in PET. NeuroImage, Poster Presentation No.: P102 Methodology.</mixed-citation>
              </ref>
              <ref id="b0250">
                <element-citation publication-type="journal" id="h0250">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ziai</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Hayeri</surname>
                      <given-names>M.R.</given-names>
                    </name>
                    <name>
                      <surname>Salei</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Salavati</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Houshmand</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Alavi</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Teytelboym</surname>
                      <given-names>O.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology</article-title>
                  <source>Radiographics</source>
                  <volume>36</volume>
                  <year>2016</year>
                  <fpage>481</fpage>
                  <lpage>496</lpage>
                  <pub-id pub-id-type="pmid">26963458</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="s0155" sec-type="supplementary-material">
              <label>Appendix A</label>
              <title>Supplementary data</title>
              <p id="p0250">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.doc"/></supplementary-material></p>
            </sec>
            <ack id="ak005">
              <title>Acknowledgements</title>
              <p id="p0240">We acknowledge the support from the Biostatistical Consulting Core at the School of Medicine, Stony Brook University with special thanks to Dr. Jie Yang and Chencan Zhu. Thank you to the clinical team, integral to participant coordination, screening and symptom scale rating: Juhayer Alam, Kate Bartolotta, Dr. Yashar Yousefzadeh Fard, Michala Godstrey, Qurat-ul-ain Gulamhussein, Nichole Hoehn, Dan Holzmacher, Dr. Sridhar Kadiyala, Dr. Laura Kunkel, Dr. Lucian Manu, Colleen Oliva, Jennifer Rubinstein, Nehal Vadhan.</p>
            </ack>
            <fn-group>
              <fn id="s0150" fn-type="supplementary-material">
                <label>Appendix A</label>
                <p id="p0245">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nicl.2021.102858" id="ir020">https://doi.org/10.1016/j.nicl.2021.102858</ext-link>.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
